Trial Profile
Dendritic cell-based Immunotherapy in patients with primary glioblastoma multiforme -Phase I/IIa clinical trial.
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 18 Sep 2019
Price :
$35
*
At a glance
- Drugs Dendritic cell vaccine-CreaGene (Primary)
- Indications Glioblastoma
- Focus Adverse reactions; Therapeutic Use
- 17 Sep 2015 Changed linked RDI profile from 36305 to 26658
- 28 Apr 2014 Status changed from recruiting to active, no longer recruiting as reported by Korean Clinical Trials Register.
- 09 May 2012 Status changed from not yet recruiting to recruiting as reported by Korean Clinical Trials Register